Egolum, Ugochukwu O. MD, FACC1; Cates, Drew W. PharmD, AAHIVP2; McGraw-Senat, Candis PharmD, BCACP2; Ling, Hua PharmD, MS, BCPS, BCCP, AACC, CLS2
1Advanced Heart Failure Section, The Heart Center of Northeast Georgia Medical Center, Gainesville, GA
2Department of Pharmacy Practice, School of Pharmacy, Philadelphia College of Osteopathic Medicine, Suwanee, GA
U. O. Egolum consults/advisory board for Akcea Therapeutics, Alnylam, AstraZeneca and Pfizer. H. Ling serves on an advisory board for Alnylam. The remaining authors have no conflicts of interest to declare.
